Clinical trial

Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data

Name
B2061147
Description
The primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to assess overall clinical benefit of antidepressant therapy in real-world practice.
Trial arms
Trial start
2022-07-04
Estimated PCD
2022-11-03
Trial end
2022-11-03
Status
Completed
Treatment
Escitalopram
Treatment for depression
Arms:
1. Escitalopram Cohort
Paroxetine
Treatment for depression
Arms:
2. Paroxetine Cohort
Fluoxetine
Treatment for depression
Arms:
3. Fluoxetine Cohort
Mirtazapine
Treatment for depression
Arms:
4. Mirtazapine Cohort
Duloxetine
Treatment for depression
Arms:
5. Duloxetine Cohort
Sertraline
Treatment for depression
Arms:
6. Sertraline Cohort
Venlafaxine
Treatment for depression
Arms:
7. Venlafaxine Cohort
Tianeptine
Treatment for depression
Arms:
8. Tianeptine Cohort
Vortioxetine
Treatment for depression
Arms:
9. Vortioxetine Cohort
Desvenlafaxine
Treatment for depression
Arms:
10. Desvenlafaxine Cohort
Bupropion
Treatment for depression
Arms:
11. Bupropion Cohort
Size
405349
Primary endpoint
Proportion of antidepressants
90 days
Dosage: Index date
90 days
Dosage: Acute treatment phase
90 days
Persistence: Average length of treatment
6 months
Discontinuation
90 days
Adherence
90 days
Recurrence
6 months
Adverse outcomes
6 months
Eligibility criteria
Inclusion Criteria Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Patients aged 18 years or older on the index date 2. Patients who had at least one inpatient claim or two outpatient claims in the intake period with any of the following diagnosis codes F06.3 Organic mood \[affective\] disorders F32\* Depressive episode F33\* Recurrent depressive disorder F34.1 Neurotic depression F38.1 Other recurrent mood \[affective\] disorder F41.2 Mixed anxiety and depressive disorder 3. Patients prescribed any of the following antidepressant during intake period (from January 1, 2017 to June 30, 2018) Exclusion Criteria Patients meeting any of the following criteria will not be included in the study: 1. Patients with a claim of diagnosis codes in Table 1 during the 12 month pre-index period 2. Patients with a claim of prescription in Table 2 during the 12 month pre-index period 3. Patient who had a claim as a beneficiary of Medical Aid program (Korean Medicaid program with free or minimum copay) 4. Patients who are hospitalized at the index date 5. Patients who are under hospice care (procedure codes WG\*-WO\*)
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 405349, 'type': 'ACTUAL'}}
Updated at
2022-11-16

1 organization

11 products

1 indication

Organization
Pfizer
Product
Paroxetine
Product
Duloxetine
Product
Tianeptine
Product
Fluoxetine
Product
Sertraline
Product
Bupropion